CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharmacyclics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharmacyclics, Inc.
995 E ARQUES AVE
Phone: (408) 774-0330p:408 774-0330 SUNNYVALE, CA  94085-4521  United States Ticker: PCYCPCYC

This company was Merged or Acquired on 5/26/2015.
This company ceased filing statements with the SEC on 6/5/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Pharmacyclics, Inc. is a United States-based biopharmaceutical company engaged in developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.  The Company designs, develops and commercializes therapies intended to improve quality of life, increase duration of life and resolve unmet medical healthcare needs of the patients. The Company also identifies and controls product candidates based on scientific development and administrational expertise. On November 13, 2013, the United States Food and Drug Administration approved IMBRUVICATM under accelerated approval as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL).  On November 13, 2013, the Company launched, developed, and commercialized its first product, IMBRUVICATM in the United States. In addition to IMBRUVICATM, the Company has three other product candidates in clinical development and other preclinical molecules in lead optimization.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201512/31/2014YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Robert W.Duggan 70 2/12/2009 9/19/2007
Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer ManmeetSoni 37 2/4/2014 2/1/2013
Chief Operating Officer MahkamZanganeh 44 8/1/2012 12/1/2010
7 additional Officers and Directors records available in full report.

Business Names
Business Name
PCYC
Pharmacyclics (Europe) Ltd.
Pharmacyclics (Shanghai) Management Consulting Service Limited
Pharmacyclics Cayman Ltd.
Pharmacyclics Switzerland GmbH
Pharmacyclics, Inc.

General Information
Stock Exchange: NASD
Federal Tax Id: 943148201
Fax Number: (408) 774-0340
Email Address: info@pcyc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023